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Abstract: Plants and plant extracts play a crucial role in the research into novel antineoplastic
agents. Four sesquiterpene lactones, artecanin (1), 3β-chloro-4α,10α-dihydroxy-1α,2α-epoxy-
5α,7αH-guaia-11(13)-en-12,6α-olide (2), iso-seco-tanapartholide 3-O-methyl ether (3) and
4β,15-dihydro-3-dehydrozaluzanin C (4), were isolated from two traditionally used Asteraceae
species (Onopordum acanthium and Artemisia asiatica). When tested for antiproliferative action on
HL-60 leukemia cells, these compounds exhibited reasonable IC50 values in the range 3.6–13.5 µM.
Treatment with the tested compounds resulted in a cell cycle disturbance characterized by increases
in the G1 and G2/M populations, while there was a decrease in the S phase. Additionally, 1–3 elicited
increases in the hypodiploid (subG1) population. The compounds elicited concentration-dependent
chromatin condensation and disruption of the membrane integrity, as revealed by Hoechst
33258–propidium staining. Treatment for 24 h resulted in significant increases in activity of
caspases-3 and -9, indicating that the tested sesquiterpenes induced the mitochondrial pathway of
apoptosis. The proapoptotic properties of the sesquiterpene lactones were additionally demonstrated
withannexin V staining. Compounds 1 and 2 increased the Bax/Bcl-2 expression and decreased
the expressions of CDK1 and cyclin B2, as determined at the mRNA level by means of RT-PCR.
These experimental results indicate that sesquiterpene lactones may be regarded as potential starting
structures for the development of novel anticancer agents.
Keywords: sesquiterpenes; leukemia cells; cell cycle; apoptosis
1. Introduction
Cancerous disorders are the leading cause of death in economically developed areas of the world
and the second cause of mortality in developing countries. In the developing world, the cancer burden
is increasing as a result of multiple factors, including the adoption of a “westernized” lifestyle. In 2008,
there were 12.4 million newly diagnosed cancers and 7.6 million cancer-related deaths worldwide, and
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it is estimated that these values will increase to 26.4 and 17 million, respectively, by 2030 [1]. Both
the current state and the tendencies in the global cancer data clearly indicate that the preventive and
therapeutic modalities utilized at present are suboptimal, and novel modes of intervention are called
for, including innovative drugs with improved efficacy profiles.
The plant kingdom is a well-established and abundant source of drug candidates, and the
systematic screening of plant preparations is therefore a widely accepted approach for the identification
of original compounds with promising pharmacological properties. A number of the currently used
anticancer drugs (e.g., Vinca alkaloids, podophyllotoxin analogs or taxanes) were discovered in
ethnomedicinally fortified screening programs of higher plants [2]. The initially identified natural
product frequently exhibits auspicious activity, but with poor pharmacokinetic properties, and chemical
derivatization is needed to obtain novel analogs suitable for further drug development. A recent
comprehensive analysis revealed that only 6% of the currently used drugs are unmodified natural
products, whereas 27% of them are closely related to a natural prototype and a further 30% were
designed on the basis of a natural pharmacophore element. Approximately two-thirds of the present
therapeutic armamentarium is therefore naturally derived or inspired, and this is especially true in
regard to concerns anticancer agents [3].
It is estimated that the plant kingdom numbers around 250,000 species, of which approximately
6% have been studied for biological activity, and about 15% phytochemically. The Asteraceae
comprise one of the largest families of higher plants, with over 13,000 species worldwide [4].
From a phytochemical aspect, the members of the family are outstandingly rich in secondary
metabolites, including sesquiterpene lactones, flavonoids, polyacetylenes, lignans and pentacyclic
triterpene alcohols [5]. Since many of the plants of the family are used ethnomedicinally for a
wide array of indications, including malignant disorders [6], but only limited data are available
concerning the antiproliferative properties of the European species, a broad systematic screening
program was earlier initiated by our group [7,8]. More than 400 extracts were prepared from 51
Asteraceae species found in Central and Eastern Europe and were tested for antiproliferative and
cytostatic effects on human adherent cancer cell lines. As a continuation of this work, several of
the active extracts were subjected to activity-guided fractionation and isolation of the constituents
responsible for the detected antiproliferative action. This resulted in new natural products and also
known substances described first from the investigated plant [9,10]. One of the recently investigated
plants was Artemisia asiatica, which has been utilized in traditional Asian medicine for many
diseases, including cancers. A formulated extract is available in South Korea for the treatment of
gastroduodenal injuries, but its cancer-preventive activity has also been demonstrated in animal
tumor models [11,12]. From an extract of the A. asiatica herb, two guaianolides, artecanin (1)
and 3β-chloro-4α,10α-dihydroxy-1α,2α-epoxy-5α,7αH-guaia-11(13)-en-12,6α-olide (2), and the
seco-guaianolide iso-seco-tanapartholide 3-O-methyl ether (3) were recently isolated and demonstrated
to exert antiproliferative actions against human adherent cancer cell lines [13]. Onopordum acanthium
is another medicinal plant belonging in the Asteraceae family which has documented anticancer
properties, and from this a fourth sesquiterpene lactone, 4β,15-dihydro-3-dehydrozaluzanin C (4), was
isolated and tested in similar methods [14] (Figure 1).
Figure 1. Chemical structures of the investigated sesquiterpenes.
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The aim of our current investigations was to extend the investigations of these sesquiterpenes by
testing their activities on the growth of HL-60 human promyelocytic leukemia cells. The most potent
agents were subjected to additional in vitro experiments in order to elucidate their mechanisms of
action. A set of sesquiterpene lactones were earlier found to be more effective on HL-60 leukemia cells
than against a panel of adherent cells [15].
2. Results and Discussion
2.1. Antiproliferative Assay
The antiproliferative effects of the tested sesquiterpenes were determined by counting HL-60 cells
after 24, 48 and 72 h of exposure, and the 72-h results were used to calculate IC50 values (Figure 2).
Compounds 3 and 4 proved to be more potent than 1 and 2, which is in good agreement with our
previous data on adherent human cancer cell lines [13,14].
Figure 2. Concentration–response curves of 1–4 after incubation for 24 (
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2.3. Cell Cycle Analysis
The effects of the tested compounds on the cell cycle distribution were determined by means of
flow cytometry. HL-60 cells were treated with the compounds at 5 and 10 µM for 24 and 48 h and the
cell populations in the various cell cycle phases (subG1, G1, S and G2/M) were measured.
Each of the four sesquiterpenes caused a concentration-dependent disturbance of the cell cycle
distribution (Figures 4 and 5). In general, the most pronounced results of treatment were increases in
the G1 and G2/M populations, while the number of cells in the S phase was decreased. The action
on the G2/M population was typically more substantial after 48 h than after 24 h of incubation,
which could indicate a cell cycle arrest at the G2/M phase. The hypodiploid (subG1) population was
additionally determined and a concentration and exposure-dependent increase was observed after 48 h
of incubation. This latter action was a pronounced exception for 4 (Figure 6). Shorter (24 h) exposure
did not result in a substantial increase in subG1 cells (data not shown).
Figure 4. Cell-cycle distributions of HL-60 cells after treatment with 1–4 for 24 and 48 h. Open, gray
and black columns indicate data from control cells and cells treated with 5 or 10 µM test substance,
respectively. * and ** denote p < 0.05 and p < 0.01, respectively, as compared with the control condition.
Data are means ˘ SEM from three determinations.
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Figure 5. Representative cell-cycle histograms of control HL-60 cells after treatment with 5 or 10 µM
1–4 for 48 h.
Figure 6. Hypodiploid (subG1) population of HL-60 cells after treatment with 1–4 for 48 h (upper
panel). ** denotes p < 0.01 as compared with the control condition. Data are means ˘ SEM from three
determinations. Histograms representing the same conditions (lower panel).
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2.4. Fluorescent Staining
HL-60 cells were incubated with 5 and 10 µM sesquiterpenes for 24 and 48 h and double-stained
with fluorescent DNA markers (Hoechst 33258 and propidium iodide (PI)) to evaluate the
morphological consequences. More intensive staining with Hoechst 33258 can be interpreted as a
consequence of nuclear condensation. Separate pictures were taken illustrating the Hoechst 33258 and
PI fluorescence as morphological markers. The extents of nuclear fragmentation and condensation were
concentration-dependent for all four natural products after both incubation times, but were relatively
independent of time after 24 h (Figure 7). Treatment-related impairment of the membrane function
was detected using more intense PI staining, which was concentration- and exposure-dependent.
Treatment with 3 or 4 resulted in profoundly disturbed membrane permeability, indicating a higher
contribution of necrosis induction.
Figure 7. Fluorescence microscopic images of sesquiterpenes 1–4 after incubation for 24 and 48 h. Two
separate pictures from the same field were taken for the two markers. The blue fluorescence (left
panels) relates to Hoechst 33258, and the red coloration (right panels) reflects cellular PI accumulation.
The bar in the PI control picture indicates 100 µm.
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2.5. Determination of Caspase-3 and Caspase-9 Activities
Most of the current drugs applied in tumor therapy have the capacity to initiate apoptotic cell
death, and the resultant controlled self-disassembly of the cancer cell is more advantageous to the
surrounding intact cells than if necrosis occurs. A potential anticancer lead compound is expected
to induce programmed cell death by modifying the balance between apoptotic and antiapoptotic
signaling. Demonstration of a proapoptotic property is therefore a crucial part of the investigation of a
novel potential antiproliferative drug candidate [16]. Although an increase in the subG1 population is
also a generally accepted marker of apoptosis, one of the most reliable indicators of this is activation of
the specific enzymes involved in the controlled cellular decomposition.
Caspases are cysteinyl aspartate proteases with elementary functions in the apoptotic machinery.
The 18 mammalian caspases are classified as initiator or executioner caspases according to their role in
the procedure [17].
Since no substantial incubation time-dependent differences were revealed by cell cycle analysis
and fluorescence microscopy after 24 h, the activities of the crucial caspases were determined only after
a 24-h exposure. All four sesquiterpenes resulted in a significant increase in the activity of the main
executionary isoenzyme caspase-3, the effects of 1 and 2 proving more pronounced (Figure 7). In the
cases of 3 and 4, the action at 10 µM was less marked than that at 5 µM. 1–4 all increased the activity of
caspase-9, the initiator enzyme of the intrinsic pathway of apoptosis [17], though less extensively than
in the case of caspase-3 (Figure 8). Caspase-9 is the first element in a cascade, whereas caspase-3 is a
terminal element, i.e., a product of amplification.
Figure 8. Induction of caspase-3 and caspase-9 activities after incubation with compounds 1–4 for
24 h. White, gray and black columns denote the control, or 5 and 10 µM sesquiterpene, respectively.
* and ** denote p < 0.05 and p < 0.01, respectively, as compared with the control condition. The activities
of caspase-3 and caspase-9 were determined with fluorimetric and colorimetric assay kits, respectively.
Data are means ˘ SEM from three determinations.
2.6. Flow Cytometric Apoptosis Assay
The proapoptotic potentials of 1–4 were further investigated by means of annexin V-Alexa 488
and PI staining, followed by flow cytometry. Treatment with each of the natural products resulted
in concentration- and time-dependent increases in annexin V-positive cells (Figure 9). 1–4 elicited
significant increases after 24 h of treatment, even at the lowest concentration used (5 µM). Annexin
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V positivity indicates the loss of physiological phospholipid asymmetry maintained by the enzyme
aminophospholipid translocase. During the early stages of programmed cell death, phosphatidylserine
is exposed to the outer surface of the cell membrane and this phenomenon is considered to be a
biochemical apoptotic marker [18].
Figure 9. Proportion ofannexin V positivity after incubation with compounds 1–4 for 24 and 48 h
(upper panels). * and ** denote p < 0.05 and p < 0.01, respectively, as compared with the control
condition. Baseline values have been subtracted from treated values. Data are means ˘ SEM from
three determinations. Representative dot-plots from 48-h treatments (lower panels).
2.7. RT-PCR Studies
The mitochondria can be considered the central hub in the regulation of the apoptosis–survival
balance. The intrinsic pathway of apoptosis is triggered by the release of cytochrome c and the
subsequent recruitment of executionary proteins. This initiating function of the mitochondria
is governed by the members of the Bcl-2 protein family, including antiapoptotic factors Bcl-2,
Bcl-xl and Mcl-1 and the proapoptotic members Bax and Bak [19]. Bax and Bcl-2 are the most
frequently investigated members of the family and their ratio is regarded as a descriptor of the
actual apoptotic–survival state.
Sesquiterpenes 1 and 2 were selected for determination of the mRNA-level expression of these
factors. A 24-h treatment with 1 resulted in an increase in the calculated ratio Bax/Bcl-2, which was
found to be significant at 10 µM, while 2 elevated this ratio at 5 µM, but not at 10 µM (Figure 10).
Compounds 1 and 2 exhibited very similar IC50 values. Although the treatment-related activation
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of both caspases was less pronounced for 2 and the higher concentration elicited only a modest
and nonsignificant change in the ratio Bax/Bcl-2, it could be concluded that this agent may induce
non-apoptotic, caspase-independent cell death, especially at higher concentrations.
Figure 10. Calculated ratios Bax/Bcl-2 at an mRNA level after incubation with compound 1 or
2 for 24 h. White, gray and black columns relate to the control, or 5 and 10 µM sesquiterpene,
respectively. * denotes p < 0.05, as compared with the control condition. Data are means ˘ SEM from
three determinations.
Since the cell cycle analysis results clearly indicate an arrest at the G2/M phase, the regulatory
background of this blockade was additionally investigated. The multiplication of the cells is a highly
complex procedure, involving a not yet completely described array of regulatory circuits. As concerns
the G2/M phase transition, the complex formed by cyclin B1, B2 and cyclin-dependent kinase 1
(CDK1) plays a crucial role [20]. The mRNA-level expressions of these three factors were additionally
determined after treatment for 24 h with 1 or 2. Both sesquiterpenes at 10 µM decreased the expression
of CDK1 and cyclin B2. The expression of cyclin B1 was increased by 1 while no considerable changes
were detected after treatment with 2 (Figure 11). Many cell-cycle-governing proteins, including these
two factors, are regulated by postsynthetic phosphorylation, and determination of the mRNA-level
expression is therefore not the optimal approach for an exact description of their function. However,
the effects of the sesquiterpenes on these factors may indicate that these natural products exert their
antiproliferative action by disturbing the cell cycle machinery.
Figure 11. Expression of CDK1, cyclin B1 and cyclin B2 at the mRNA level after incubation with 1 or 2
for 24 h. White, gray and black columns relate to the control, or 5 and 10 µM sesquiterpene, respectively.
* and ** denote p < 0.05 and p < 0.01, respectively, as compared with the control condition. Data are
means ˘ SEM from three determinations.
The plant kingdom contains a virtually inexhaustible source of natural products with attractive
pharmacological properties, which makes plant extracts suitable subjects for lead-finding studies.
The predominance of drugs that have been developed from or inspired by natural products is
especially true for anticancer agents. Such effective plant preparations may serve not only as the source
of the active agent, but additionally as a safe and cost-effective means of chemoprevention [21].
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The sesquiterpene lactones constitute a chemically diverse group of more than 5000 secondary
metabolites, most of them isolated from Asteraceaea species. These natural products possess
diverse biological activities, their anti-inflammatory and antiproliferative properties being the
most characteristic [22]. Guaianolides and pseudoguaianolides are the subclasses of sesquiterpenes
that exhibit the most pronounced cytotoxic effects, which are attributed to two main structural
components: α-methylene-γ-lactone and α,β-unsaturated cyclopentanone rings [23]. These structural
moieties, which function as alkylating agents reacting with sulfhydryl groups, are needed for
antiproliferative action. This Michael-type addition involves various intracellular targets including
mercaptyl groups of proteins, leading to the loss of enzyme activity [24]. The reaction also results
in the depletion of free intracellular glutathione, disruption of the cellular redox balance and the
consequent oxidative stress [25]. The generated reactive oxygen species have the capacity to activate
the mitochondrial pathway of apoptosis [26]. Sesquiterpenes containing an epoxide ring besides
the α-methylene-γ-lactone pharmacophore can be regarded as bifunctional molecules and more
pronounced antiproliferative action can be expected from them [24] Two of the currently investigated
natural products,1 and 2, are such sesquiterpenes. The consequences of the alkylation have been only
incompletely elucidated, but one of the best-characterized sesquiterpenes with an anticancer effect is
parthenolide, which directly inhibits NF-κB and also prevents the phosphorylation and subsequent
degradation of IκB [27,28].
The terpenes are a “drug-like” subclass of natural compounds. Ingenol mebutate, found in
Euphorbia peplus, has been registered for the treatment of premalignant lesions in actinic keratosis [29].
Orally active parthenolide derivatives have been prepared and proved selective against cancer stem
cells [28]. The water-soluble dimethylaminohydrochloride derivative of the sesquiterpene arglabin is
used in oncological practice in Kazakhstan [30]. All of our currently investigated effective molecules
contain these critical pharmacophores, as an indication that they may be regarded as potential starting
structures for the design and development of novel anticancer agents.
3. Experimental Section
3.1. Chemicals
The currently investigated sesquiterpene lactones 1–4 were isolated and identified as described
earlier [13,14]. Their chemical structures are presented in Figure 1. All other chemicals, if otherwise
not specified, were from Sigma–Aldrich (Budapest, Hungary).
3.2. Cell Culturing and Antiproliferative Assay
The human HL-60 promyelocytic leukemia cell line was purchased from the American Type
Culture Collection (Manassas, VA, USA). Cells were grown in RPMI 1640 medium supplemented with
10% heat inactivated fetal calf serum (FCS), 1% L-glutamine, and 1% penicillin-streptomycin at 37 ˝C
in a humidified atmosphere containing 5% CO2, using a Heraeus cytoperm 2 incubator (Heraeus,
Vienna, Austria). Human skin fibroblasts (Sigma–Aldrich, Budapest, Hungary) were maintained
in DMEM/F12 medium supplemented with 10% FCS. All media and supplements were purchased
from Gibco Life Technologies (Paisley, Scotland, UK). Cell counts were determined with a CC-110
microcellcounter (Sysmex, Kobe, Japan). Cells growing in the logarithmic phase of growth were used
for all experiments described below.
The antiproliferative effects of 1–4 on HL-60 cells were determined by cell counting. Briefly, cells
were seeded in 25-cm2 tissue culture flasks at a density of 750,000 cells/5 mL medium and the cells
were exposed to the tested compound. After incubation periods of 24, 48 and 72 h, the cells were
counted with a cell counter. All in vitro experiments were carried out on at least three parallel samples.
Sigmoidal dose–response curves were fitted to the measured points and IC50 values were calculated
by means of GraphPad Prism 4 software (GraphPad Software, San Diego, CA, USA).
Int. J. Mol. Sci. 2016, 17, 83 11 of 15
3.3. Cell Viability Measurements
The viability of HL-60 human leukemia cells and fibroblasts from healthy donors was determined
by the colorimetric MTS assay (Promega, Madison, WI, USA) as described earlier [31]. Briefly,
the cells (4000 HL-60 and 6000 fibroblasts) were seeded into 96-well plates in RPMI 10% FCS and
DMEM/F12 10% FCS, respectively. Cells were cultured overnight before treatment. The effects
of 1 and 2 at 0, 0.1, 0.3, 1, 3, 10 and 20 µM were examined after a 72-h incubation. The MTS
reagent (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrazolium)
was applied to drug-treated and control (0.2% DMSO) cells according to the manufacturer’s protocol.
Absorbance (at 490 nm) was recorded on a multimode microplate reader (Perkin Elmer, Waltham, MA,
USA). Viability was calculated relative to untreated control cells and blank wells containing media
without cells.
3.4. Cell Cycle Analysis by Flow Cytometry
Cellular DNA content was measured by means of flow cytometric analysis, using the DNA-specific
fluorescent dye PI. HL-60 cells (200,000) were plated in 24-well tissue culture plates (Corning Life
Sciences, Corning, NY, USA) in RPMI 10% FCS and were treated with the indicated compound
and concentrations on the graphs. After 24 or 48 h the cells were collected, washed with PBS and
resuspended in DNA binding buffer (1ˆ PBS, 0.1% trisodium citrate, 10 µg/mL PI, 0.1% Tx, 10 µg/mL
RNaseA, (Sigma–Aldrich)). After 30 min incubation at room temperature cells were acquired on a
FACSCalibur cytofluorimeter (Becton Dickinson, Franklin Lakes, NJ, USA), we gated out doublets
for cell cycle analysis which was based on FL2-A/FL2-W dot plots, using ModFit software (Verity
Software House, Topsham, ME, USA). Sub-G1 apoptotic population was analyzed on FL3 histograms
using CellQuest software (Becton Dickinson) [32].
3.5. Double Staining with Hoechst 33258 and PI
Cells were seeded into a 6-well plate and incubated with various concentrations of the tested
compounds for 24 or 48 h. Hoechst 33258 and PI were added directly to the cells to give final
concentrations of 5 and 3 µg/mL, respectively. After incubation for 60 min at 37 ˝C, the cells
were examined on a Nikon Fluorescence Microscope equipped with a Digital Sight Camera System,
including appropriate filters for Hoechst 33258 and PI [33,34].
3.6. Caspase-3 Assay
The activity of caspase-3 from treated cells was determined by means of a fluorimetric assay kit
(Sigma–Aldrich Ltd., Budapest, Hungary). Ac-DEVD-AMC was used as substrate. In the course of
the assay, the peptide substrate was cleaved by the enzyme, resulting in the release of AMC, which
was determined on a microplate reader at 360/460 nm (excitation/emission). HL-60 cells were treated
with the tested compounds at 5 and 10 µM for 24 h, untreated cells serving as control. The cells were
harvested and incubated with cell lysis buffer (in proportion to the cell number) on ice for 15 min.
The cell lysate was centrifuged (15 min, 17,000ˆ g) and the supernatant was collected and analyzed.
The results were expressed in fold increase of caspase-3 activity relative to the result of the control
condition [35].
3.7. Caspase-9 Assay
Caspase-9 activity was determined with a colorimetric assay kit (Sigma–Aldrich Ltd., Budapest,
Hungary). Ac-LEHD-pNA was used as substrate. The cleavage of the peptide substrate by caspase-9
resulted in the release of pNA, which was measured on a microplate reader at an absorbance
wavelength of 405 nm. All further conditions were identical with those in the caspase-3 assay.
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3.8. Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Studies
The actions of the investigated sesquiterpenes on the mRNA expression pattern of the markers of
apoptosis, such as Bax, Bcl-2, cyclin-dependent kinase 1 (CDK1), cyclin B1 and cyclin B2, which play
fundamental roles in the G2–M transition, were determined by RT-PCR in HL-60 cells. After a 24-h
incubation period, the medium containing the tested natural products was discarded and the total
RNA was isolated from the cells (4 ˆ 105) by using the TRIzol Reagent according to the instructions of
the manufacturer (Csertex Ltd., Budapest, Hungary). The pellet was resuspended in 100 µL DNase-
and RNase-free distilled water. The concentrations of RNA in the samples were determined from their
absorbances at 260 nm. The RNA (0.5 µg) was mixed with DNase- and RNase-free distilled water and
20 µM oligodT (Invitrogen, Carlsbad, CA, USA) in a final reaction volume of 10 µL, and incubation
was performed at 70 ˝C for 5 min. After the mixture had been cooled to 4 ˝C, 20 U MMLV reverse
transcriptase (Promega, Madison, WI, USA), 20 U RNase inhibitor (Promega, Madison, WI, USA),
200 µM dNTP (Sigma–Aldrich; Budapest, Hungary) in 50 mM Tris–HCl, pH 8.3, 75 mM KCl, and
5 mM MgCl2 in a final reaction volume of 10 µL were added. The mixture was incubated at 37 ˝C for
60 min. The reaction was performed in the presence of 5 µL cDNA, 12.5 µL GoTaq Green Master Mix,
2 µL 20 pM sense and antisense primers of Bax, Bcl-2, CDK1 and cyclin B2 and 3.5 µL DNase- and
RNase-free distilled water. Human glyceraldehyde 3-phosphate dehydrogenase (hGAPDH) primers
were used as internal control in all samples (Table 1). The reaction was performed with an ESCO SWIFT
MAXI thermal cycler (Esco Technologies Inc., Philadelphia, PA, USA) and the products were separated
on 2% agarose gels, marked with ethidium bromide and photographed under a UV transilluminator.
Semiquantitative analysis was obtained by means of densitometric scanning of the gel with Kodak
IMAGE STATION 2000R (Csertex Ltd., Budapest, Hungary) [36].
Table 1. Primers and PCR conditions of the determined genes, the Genebank access numbers and the
length of PCR products.
Name Primer Sequence Gene ID Product Size (bp) Coupling Temp. (˝C)
CDK1
F: ACTGGCTGATTTTGGCCTTGCC
983 118 62R: TGAGTAACGAGCTGACCCCAGCAA
cyclin B1 F: AATAAGGAGGGAGCAGTGCG 891 51 60R: GAAGAGCCAGCCTAGCCTCAG
cyclin B2 F: GCGTTGGCATTATGGATCG 9133 51 60R: TCTTCCGGGAAACTGGCTG
Bax
F: TGGCAGCTGACATGTTTTCTGAC
581 195 53R: CGTCCCAACCACCCTGGTCT
Bcl-2
F: GACTTCGCCGAGATGTCCAG
596 225 51R: CAGGTGCCGGTTCAGGTACT
hGAPDH
F: ACCCAGAAGACTGTGGATGG
2597 415 55R: TGCTGTAGCCAAATTCGTTG
3.9. Flow Cytometric Apoptosis Assay
HL-60 cells (200,000) were plated in 24-well tissue culture plates in RPMI medium supplemented
with 10% FCS and were treated with 1–4 in the concentrations indicated in the graphs. After 24 or
48 h, the cells were collected and resuspended in Annexin V binding buffer (0.01 M HEPES, 0.14 M
NaCl and 2.5 mM CaCl2). Annexin V-Alexa 488 (LifeTechnologies, Waltham, MA, USA) was added to
the cells, which were then kept in the dark for 15 min at room temperature. Before the acquisition, PI
(10 µg/mL) in annexin V binding buffer was added to diluted annexin V-Alexa 488 5-fold. Cells were
analyzed on a FACSCalibur cytofluorimeter, using CellQuest software (Becton Dickinson, Franklin
Lakes, NJ, USA). The percentages of the FL1 (annexin V-Alexa 488) positive and FL3 (PI) negative
early-apoptotic cells and FL1 (annexin V-Alexa 488) positive and FL3 (PI) positive late-apoptotic cells
were determined [37].
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3.10. Statistical Analysis
All in vitro experiments were performed in triplicate and statistical analysis was carried out by
ANOVA, followed by the Dunnett post-test with the use of GraphPad Prism 4 software (GraphPad
Software, San Diego, CA, USA).
4. Conclusions
Overall, the presented results indicate that sesquiterpenes 1–4 exert antiproliferative action
against HL-60 human leukemia cells. Although the sesquiterpenes are widely investigated compounds
and their anticancer action is well recognized, similar results have not been published previously
concerning 1–4. It was demonstrated that 1–4 elicited a concentration-dependent disturbance in the
cell cycle and induced apoptosis by activating the mitochondrial pathway. The presented data indicate
that these sesquiterpenes can be regarded as suitable structures for the development of novel potential
anticancer agents.
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